LIVZON PHARMA - Announcement of Livzon Pharmaceutical Group Co., Ltd. on the adjustment and extension of the duration of the second phase of the medium- and long-term business partner stock ownership plan
LIVZON PHARMA - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
does not make any representation about the accuracy or completeness of this announcement and expressly disclaims any liability arising out of or in connection with all or any part of this announcement.
We accept no liability for any loss caused by reliance on such content.
Overseas regulatory announcement
This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
This is to set forth the "Livzon Pharmaceutical Group Co., Ltd." published on the website of the Shenzhen Stock Exchange Co., Ltd.’s announcement on extending the duration of the second phase of the medium- and long-term business partner stock ownership plan” is for reference only.
By order of the board of directors
Livzon Pharmaceutical Group Co., Ltd. LivzonPharmaceuticalGroupInc.* company secretary Liu Ning
China, Zhuhai April 23, 2026
As of the date of this announcement, the executive director of the company is Mr. Tang Yanggang (vice chairman); the non-executive director of the company is Mr. Zhu Baoguo. Sheng (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the company’s employee director is Ms. Ran Yongmei; and the company’s independence is not
The executive directors are Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie and Ms. Wang Zhiyao.
*Identification only
Securities code: 000513, 01513 Securities abbreviation: Livzon Group, Livzon Pharmaceutical Announcement number: 2026-35
Livzon Pharmaceutical Group Co., Ltd.
Adjustment of relevant contents of the second phase of the medium- and long-term business partner stock ownership plan
Announcement on consolidation and extension of duration
The company and all members of the board of directors guarantee that the information disclosed is true, accurate, complete and not false. records, misleading statements or material omissions.
Livzon Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") respectively on April 22, 2026
On April 23, 2026, the second phase of the medium and long-term business partner stock ownership plan was held for the third time
The shareholders' meeting and the 34th meeting of the 11th Board of Directors reviewed and approved the "About Adjustment of the Second Phase of the Holding "Proposal on the Related Contents and Extension of the Duration of the Stock Plan" and agreed to adjust the company's medium and long-term business partner shareholding plan.
related to the second phase of the planned shareholding plan (hereinafter referred to as the "second phase of the shareholding plan" or the "current shareholding plan")
content, and extended the duration of the second phase of the shareholding plan by 12 months. The relevant matters are now announced as follows:
- Basic information of the second phase shareholding plan
The company held the 29th meeting of the 10th board of directors and the 10th board of supervisors on April 11, 2022
At the 16th meeting, the 2021 Annual General Meeting of Shareholders was held on May 20, 2022, and the "Relevant Regulations" were reviewed and approved. Discussion on the company's "Second Phase Stock Ownership Plan (Draft) of the Medium and Long-term Business Partner Stock Ownership Plan" and its summary
Case" and other related proposals. The company held the 32nd meeting of the 10th board of directors on June 15, 2022 and
The 18th meeting of the 10th Board of Supervisors will hold the first extraordinary general meeting of shareholders in 2022 on July 8, 2022.
The meeting reviewed and approved the Second Plan of the Medium and Long-term Business Partner Stock Ownership Plan of Livzon Pharmaceutical Group Co., Ltd.
Second-Term Stock Ownership Plan (Revised Draft)" (hereinafter referred to as the "Second-Term Stock Ownership Plan") and related proposals.
According to the "Second Phase Stock Ownership Plan", the company's second phase stock ownership plan sources of stocks are purchased through the secondary market.
Purchase (including but not limited to bidding transactions, bulk transactions, etc.) and other methods permitted by laws and regulations to obtain the company
A-share ordinary shares are funded by special funds set aside by the company. The current shareholding plan has been completed in 2022 The last transfer of underlying stocks was completed on August 12, and all stocks have been transferred to "CITIC Securities-Livzon Group"
Medium and long-term business partner employee stock ownership plan No. 2 single asset management plan "separate account." The current stock ownership plan
The lock-in period is 36 months, starting from the time when the company announces the transfer of the last underlying stock to the name of the current share ownership plan.
Calculated, that is, the lock-in period is from August 13, 2022 to August 12, 2025. The duration of the current share ownership plan
It is 48 months, calculated from the time when the company announces the transfer of the last underlying stock to the name of the current share ownership plan.
The original term will expire on August 12, 2026. For details, please see the company’s website on cnchao.com
(www.cninfo.com.cn) relevant announcements disclosed.
As of the disclosure date of this announcement, the current shareholding plan holds 2,057,711 A shares of the company, accounting for
0.23% of the total share capital.
- Adjustments to relevant contents of the current share ownership plan and extension of duration
According to the "Second Phase Stock Ownership Plan", the medium and long-term business partners of Livzon Pharmaceutical Group Co., Ltd. Management Measures for the Second Phase of the Stock Ownership Plan (Revised Draft)" (hereinafter referred to as the "Management Measures for the Second Phase of the Stock Ownership Plan")
Regulations) stipulates that if all the shares are not sold before the expiration of the current shareholding plan, the current shareholding plan will be
Within 10 days before the expiration of the plan’s duration, it shall be approved by more than 2/3 of the valid voting rights present at the holders’ meeting, and
Upon review and approval by the board of directors, the duration of the current share ownership plan can be extended.
As of now, the duration of the company’s second-phase shareholding plan is about to expire. Based on the company’s future development,
Confidence, according to the relevant provisions of the "Second Phase Stock Ownership Plan" and held for the third time by the company's Second Phase Stock Ownership Plan
The People's Meeting and the 34th meeting of the 11th Board of Directors reviewed and approved the "Second Phase Stock Ownership Plan"
The relevant provisions of the "Measures for the Administration of the Second Phase Stock Ownership Plan" will be modified and the duration of the second phase shareholding plan will be extended. The specific situation is as follows:
(1) Adjustments to relevant terms of the current shareholding plan and management measures
Chapter Before adjustment After adjustment "Livzon Pharmaceutical Group Shares" Before the expiration of the duration of the current share ownership plan, all of the shares have not yet been released. If the stock is sold in the medium and long term of a limited company, the current share ownership plan will continue. If all the stocks are sold, the stock ownership plan will be held after attendance. Within 10 days before the expiration of the business partner’s shareholding period, more than 2/3 of the effective voting rights of the shareholders’ meeting attended The second phase of the plan’s shareholding plan was approved by more than 2/3 of the effective voting rights, and was reviewed and approved by the board of directors. Plan (Revised Draft)" No. 5: The board of directors reviewed and approved that the duration of the current share ownership plan can be extended.
Chapter/Article 4/Paragraph 3 The duration may be extended. long. "Livzon Pharmaceutical Group Co., Ltd. Before the expiration of the duration of the current share ownership plan, the entire period of the current share ownership plan has expired. medium and long term If the shares are sold, the current share ownership plan will continue to exist. If all the shares are sold, the stock ownership plan will be held after attendance. Business partner shareholding plan Within 10 days before the expiration of the term, more than 2/3 of the valid voting rights at the holder’s meeting were attended The second phase of the shareholding plan The resolution was passed by more than 2/3 of the valid voting rights, and was reviewed and approved by the board of directors. Planning Management Measures (Revised The board of directors reviewed and approved that the duration of the current share ownership plan can be extended. Draft)》Chapter 2/Article 9 The duration can be extended. long. /Article 3
(2) According to the above revised terms, it is agreed to extend the duration of the current share ownership plan by 12 months, that is, to extend
Until August 12, 2027.
The adjustments to the relevant contents of this shareholding plan and the extension of the duration are in compliance with the "On the Implementation of Employee Implementation of Listed Companies"
Guiding Opinions on the Pilot of Stock Ownership Plans" "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 -
According to the "Standardized Operation of Main Board Listed Companies" and the relevant documents of the company's shareholding plan, the review process is legal and compliant.
Except for the aforementioned adjustments, other contents of the current shareholding plan remain unchanged.
- Other instructions
The current shareholding plan can choose the opportunity to sell the shares during the extended duration according to relevant regulations and market conditions.
Company stock held. The company will continue to pay attention to the implementation progress of the current shareholding plan and strictly follow the relevant
Fulfill information disclosure obligations in a timely manner in accordance with relevant laws, regulations and normative documents. Investors are kindly requested to pay attention to the relevant Please read the relevant announcements and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Livzon Pharmaceutical Group Co., Ltd.
April 24, 2026